Indivior PLC - Virginia, US-based pharmaceutical company - Reported a steep 33% fall in net revenue in the six months ended June 30 to GBP303 million from GBP454 million the year before. Indivior swung to a pretax loss of GBP171 million from a GBP166 million profit. The firm reported a decline in market share of its Suboxone film opioid treatment to 21% at the end of the half, from 27% a year prior. It also reported that the cancellation of its generic opioid treatment film buprenorphine in the fourth quarter of 2019 helped drag first half US net revenue down 42%.
Current stock price: 144.30 pence
Year-to-date change: up sharply from 39.00p
By Neetika Kurup; neetikakurup@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Indivior (INDV)